Sage Journals: Discover world-class research

Abstract

Study investigates the role of endothelin (ET) receptors in mediating early changes in cerebral blood flow—as measured by laser Doppler flowmetry (CBF_LDF)—during experimental pneumococcal meningitis. Meningitis was induced with heat-killed pneumococci and confirmed by a significant increase in CBF_LDF (baseline 100%; 225.3 ± 21.8% after 6 hours; mean ± SD), intracranial pressure (ICP), brain water content, and white blood cell count in the CSF. Intravenous administration of the selective endothelin B (ET_B) receptor antagonist BQ-788 immediately before pneumococcal challenge (but not 4 hours afterward) significantly attenuated these pathophysiologic alterations (e.g., CBF_LDF 6 hours after pneumococcal challenge: 116.7 ± 17.4%). Pretreatment with BQ-123, a selective endothelin A receptor antagonist, had no significant effect on ICP and brain water content, but augmented the increase in CBF_LDF and CSF white blood cell count. Since ET is known to trigger the release of nitric oxide (NO) by ET_B receptor activation, we examined specific ET–NO interactions in primary rat cerebromicrovascular endothelial cells after stimulation with heat-killed pneumococci. Pneumococci induced a significant increase in both ET and NO concentrations in endothelial cell culture medium. Treatment with phosphoramidon, an inhibitor of the endothelin-converting enzyme, prevented the production of endothelin and markedly reduced NO generation. Our data provide evidence that ET is involved as a mediator in early pneumococcal meningitis in the rat and contributes to the increase in CBF_LDF, ICP, brain water content, and CSF pleocytosis, presumably through ET_B receptor–mediated NO production.

Keywords

Pneumococcal meningitis Endothelin B receptor Endothelin A receptor Endothelin Nitric oxide Endothelial cell culture Rat

Bacterial meningitis from Streptococcus pneumoniae infection remains an important cause of mortality and morbidity (Quagliarello and Scheld, 1992). The unfavorable clinical outcome often results from cerebrovascular alterations, brain edema, and raised intracranial pressure (ICP) (Durand et al., 1993). In the last several years, animal studies have provided much insight into the pathophysiologic mechanisms of these intracranial complications. The early phase of experimental pneumococcal meningitis is characterized by an increase in cerebral blood flow, ICP, brain water content, and the migration of leukocytes into the subarachnoid space (Pfister et al., 1990; Weber et al., 1996). The molecular mechanisms underlying these changes involve both bacterial components and host factors such as arachidonic acid metabolites, cytokines, reactive oxygen species, and nitric oxide (NO), as well as leukocyte–endothelial interaction (Tuomanen et al., 1989; Saukkonen et al., 1990; Pfister et al., 1990; Koedel et al., 1995).

Several arguments suggest that endothelin (ET) may be involved in the complex inflammatory network of early pneumococcal meningitis. In the cerebral vasculature, intraluminal ET has been found to elicit vasodilation through the induction of NO and prostanoids through an activation of the endothelin B (ET_B) receptor (Kobari et al., 1994a,b). In addition, ET can cause an increase in blood–brain barrier permeability (Stanimirovic et al., 1993) and plasma protein extravasation in rat dura mater (Brändli et al., 1996). Besides its role as a regulator of the vascular tone and integrity, recent findings strongly indicate that ET is a mediator of inflammation: bacterial cell wall components, inflammatory cytokines, and neutrophil–endothelial interactions can stimulate ET production (Ehrenreich et al., 1990; Corder et al., 1995). Neutrophil lysosomal proteases can convert the propeptide big-ET into the mature ET. Moreover, ET interacts at the level of biosynthesis and biological actions with a variety of substances involved in the pathophysiologic mechanisms of pneumococcal meningitis such as arachidonic acid metabolites, cytokines, and NO (Rubanyi and Polokoff, 1994). A further sign that ET possibly plays a pathophysiologic role in meningitis is the occurrence of elevated ET levels in CSF samples of patients with bacterial meningitis that were obtained at the time of admission to the hospital (Koedel et al., 1997).

This study investigates the role of ET receptors in mediating pathophysiologic alterations during experimental pneumococcal meningitis.

METHODS

Rat model of pneumococcal meningitis

A well-characterized rat model of bacterial meningitis was used in this study, which was previously described in detail (Pfister et al., 1990; Koedel et al., 1995). The protocols of this study were approved by the Government of Upper Bavaria. Thirty-two male Wistar rats (250 to 300 g) were anesthetized with 100 mg/kg thiopental (Byk Gulden, Konstanz, Germany) before undergoing tracheotomy, and then given artificial ventilation with a small animal ventilator (AP-10; K. Effenberger, Pfaffing, Germany). The MABP was measured through a cannula inserted into the right femoral artery using a pressure transducer (Statham P23, Viggo-Spectramed, Oxnard, CA, U.S.A.). Arterial blood samples were drawn at the beginning and the end of each experiment as well as every 2 hours and were analyzed for arterial Paco₂, Pao₂, and pH with a blood gas analyzer (IL 1304, Instrumentation Laboratory, Kirchheim, Germany). The right femoral vein was cannulated for fluid substitution and drug administration. Body temperature was monitored and maintained at 38.0° ± 0.5°C using a heating pad. The CSF samples were collected for white blood cell (WBC) count before and 6 hours after pneumococcal challenge. The ICP was recorded throughout the experiment with a pressure transducer (Statham P23, Viggo-Spectramed) connected to a cisterna magna catheter placed through a burr hole in the occipital bone (Pfister et al., 1990). For placement of the laser Doppler probe, a 5 × 4 mm area of the right parietal bone was gently abraded to a transparent bone layer while continuously rinsing with saline for cooling. The laser Doppler probe (model BPM 403a, vasamedics, St. Paul, MN, U.S.A.) held by a micromanipulator was placed over an area free of large dural and pial vessels according to the description of Weber et al (1996). Cerebral blood flow, as measured continuously by laser Doppler flowmetry (CBF_LDF), was expressed as percentage of a stable baseline of 100% (Pfister et al., 1990).

At the end of the experiment, rats were killed by exsanguination, and brain water content, a parameter for brain edema formation, was determined as described previously (Pfister et al., 1990).

Induction of meningitis

When stable baselines of CBF_LDF and ICP were achieved for 30 minutes, 100 μL CSF were removed through the cisterna magna catheter. Meningitis was induced by the intracisternal injection of 100 μL 10⁸ colony forming units (cfu)/mL heat-killed pneumococci (HKP). The preparation of pneumococci used in this study was previously described in detail (Koedel et al., 1995). Heat-killed (60°C for 4 hours), unencapsulated pneumococci stem from an isogenic mutant of the encapsulated strain S pneumoniae serotype 3 (no. 17260) (Koedel et al., 1995).

Experimental protocol of in vivo investigations

Rats were divided into the following experimental groups (seven total): group 1, untreated rats injected intracisternally with HKP (n = 8); group 2, rats injected intracisternally with HKP and pretreated with a selective ET_B receptor antagonist, BQ-788 (n = 5) (Ishikawa et al., 1994); group 3, rats injected intracisternally with HKP and treated with BQ-788 4 hours after intracisternal challenge (n = 4); group 4, rats injected intracisternally with HKP and pretreated with a selective endothelin A (ET_A) receptor antagonist, BQ-123 (n = 7). To determine whether ET receptor antagonists by themselves can influence CBF_LDF, ICP, brain water content, or CSF WBC count, we investigated the following control groups: group 5: untreated rats injected intracisternally with phosphate-buffered saline (PBS) (control; n = 3); group 6: control rats pretreated with BQ-788 (n = 3); and group 7: control rats pretreated with BQ-123 (n = 3). Both ET receptor antagonists were given intravenously in a dosage of 0.3 mg/kg as bolus injection, followed by a continuous infusion of 0.3 mg/kg/h, similar to Ishikawa and others (Ishikawa et al., 1994).

In vitro experiments

Recent studies provide evidence that the cerebral microvascular endothelium plays a central role in the pathophysiologic mechanism of pneumococcal meningitis: namely, in the entry of bacteria into the CSF, the synthesis and release of inflammatory mediators, the adhesion and transmigration of leukocytes, and the breakdown of the blood–brain barrier (Quagliarello et al., 1986; Saukkonen et al., 1990; Koedel et al., 1995. Tuomanen, 1996). Cerebral microvascular endothelial cells can synthesize and release ET, and express both ET_A and ET_B receptors (Yoshimoto et al., 1990; Nilsson et al., 1997). Stimulation of ET_B receptors in endothelial cells can induce the release of NO (Hirata et al., 1993). In recent studies, we showed that HKP can induce cerebral microvascular endothelial cells to produce NO, and that NO is a key mediator of early pathophysiologic alterations in pneumococcal meningitis (Koedel et al., 1995). Thus, we tested whether HKP can stimulate cerebral microvascular endothelial cells to release ET, and whether the release of both ET and NO can be modulated either by N^ω-nitro-l-arginine (l-NA), an NO synthase inhibitor, or by phosphoramidon, a metalloproteinase inhibitor capable of inhibiting the endothelin-converting enzyme.

Preparation of cerebromicrovascular endothelial cells

Endothelial cells from cerebral microvessels were isolated from 3-week-old Wistar rats as previously described (Koedel et al., 1995). Cortical tissue was cleaned of meninges and superficial vessels with fine forceps under a binocular microscope. The hemispheres were incubated with 0.75% collagenase for 1 hour at 37°C. After centrifugation with 25% bovine serum albumin for 20 minutes at 800 × g, the cell suspension was incubated with 0.1% collagenase/dispase (Boehringer Mannheim, Germany) for 30 minutes at 37°C. After centrifugation, the pellet was fractionated with a 33.3% Percoll gradient. The cell layer of the gradient was plated in Dulbecco's modified Eagle's medium (Biochrom, Berlin, Germany) and then supplemented with 20% fetal calf serum (Biochrom) and 25 μg/mL endothelial cell growth factor (Boehringer Mannheim). After 3 to 5 days, the endothelial cells formed a confluent monolayer (approximately 5 × 10⁵ cells/well). All monolayers were characterized as endothelial cells by morphologic criteria and the ability to bind antibody to von Willebrand factor (Boehringer Mannheim). For the experiments, monolayers without any passage were washed with PBS without Ca²⁺ or Mg²⁺ and maintained in Dulbecco's modified Eagle's medium with 20% fetal calf serum and 20 μg/mL endothelial cell growth factor without antibiotics and phenol red.

Experimental groups of in vitro experiments

The following three groups were investigated: endothelial cells stimulated with 10⁷ cfu/mL HKP that were 1) untreated (n = 8), 2) treated with l-NA (1 mmol/L; n = 6), or 3) treated with phosphoramidon (100 μmol/L; n = 6). Endothelial cells cultured in the absence of HKP (n = 6) were negative controls, and endothelial cells stimulated with thrombin (10 U/mL; n = 6), a known inducer of ET release, were positive controls. Both ET and nitrite concentrations in the cell culture medium were measured 48 hours after stimulation. To investigate whether HKP influenced ET concentrations, ET levels were determined in the cell culture medium in the absence of endothelial cells after incubation with 10⁷ cfu/mL HKP (n = 4) and compared with cell culture medium alone (n = 4).

Determination of nitrite and endothelin concentrations in the cell culture medium

The NO production was assessed by measuring nitrite, a stable metabolic product of NO, using the Griess reaction (Koedel et al., 1995). The ET concentrations in cell culture medium were measured by a radioimmunoassay as described previously (Arendt et al., 1993). For determining nitrite and ET, detection limits of 0.2 μmol/L and 1 pmol/L, respectively, were found for the test samples.

Reagents

We used BQ-123, a selective ET_A antagonist, and BQ-788, a selective ET_B antagonist from Alexis (Grünberg, Germany), as well as the metalloproteinase inhibitor phosphoramidon and the nitric oxide synthase inhibitor l-NA from Sigma Chemicals (Deisenhofen, Germany).

Statistical analysis

For statistical analysis, data on CBF_LDF and ICP obtained 3 hours and 6 hours after intracisternal pneumococcal challenge were compared by one-way analysis of variance and Scheffe's test. P values were corrected for repeated measures using the Bonferroni-Holm procedure. One-way analysis of variance and Scheffe's test were applied for statistical analysis of data on brain water content, CSF WBC count, and concentrations of ET and NO/nitrite in cell culture medium. To detect changes over time within the control group (group 5) in the in vivo experiments, data were compared using repeated measures analysis of variance. A P value < 0.05 was considered significant. Data are given as mean ± SD.

RESULTS

In vivo experiments

Mean arterial blood pressure, Pao₂, Paco₂, pH, and hematocrit were within normal ranges throughout the experiment (Table 1). Small differences between groups were not statistically significant.

TABLE 1.

Physiologic parameters in different experimental groups

	Mean arterial blood pressure (mm Hg)		Paco₂ (mm Hg)		Pao₂ (mm Hg)		pH		Hematocrit (%)

Group	Baseline	6 h	Baseline	6 h	Baseline	6 h	Baseline	6 h	Baseline	6 h
HKP-injected, untreated (n = 8)	117 ± 12	103 ± 10	40 ± 4	37 ± 5	142 ± 25	143 ± 24	7.40 ± 0.03	7.40 ± 0.04	47 ± 1	46 ± 1
HKP-injected, pretreated with BQ788 (n = 5)	112 ± 6	106 ± 10	39 ± 3	39 ± 6	131 ± 12	136 ± 35	7.43 ± 0.05	7.41 ± 0.02	47 ± 1	46 ± 1
HKP-injected, treated with BQ788 at 4 h (n = 4)	112 ± 6	102 ± 8	36 ± 4	38 ± 4	143 ± 33	139 ± 35	7.43 ± 0.03	7.41 ± 0.04	47 ± 1	45 ± 1
HKP-injected, pretreated with BQ123 (n = 7)	119 ± 10	107 ± 5	42 ± 4	39 ± 5	134 ± 24	138 ± 17	7.39 ± 0.01	7.38 ± 0.03	47 ± 1	46 ± 1
PBS-injected, pretreated with BQ788 (n = 3)	118 ± 9	102 ± 11	39 ± 2	37 ± 5	144 ± 22	133 ± 23	7.39 ± 0.02	7.42 ± 0.04	47 ± 1	46 ± 1
PBS-injected pretreated with BQ123 (n = 3)	122 ± 6	104 ± 8	36 ± 4	37 ± 5	143 ± 33	136 ± 38	7.43 ± 0.03	7.41 ± 0.04	47 ± 1	45 ± 1
PBS-injected, untreated (n = 3)	124 ± 14	103 ± 16	40 ± 2	43 ± 3	145 ± 6	137 ± 5	7.42 ± 0.02	7.40 ± 0.02	47 ± 1	46 ± 1

In untreated rats injected intracisternally with PBS (control rats), there was no significant change in CBF_LDF or ICP throughout the experiment, and they did not develop CSF pleocytosis. Brain water content measured in control rats was 77.41 ± 0.16%. In rats injected intracisternally with PBS, systemic administration of neither BQ-788 nor BQ-123 led to changes in CBF_LDF, ICP, brain water content, or CSF WBC count (P > 0.05, compared with untreated control rats; Table 2).

TABLE 2.

Effect of endothelin receptor antagonists BQ-788 and BQ-123 in experimental meningitis

	Intracranial pressure (mm Hg)			Brain water content (%)	CSF white blood cells (cells/μL)

Group	Baseline	3 h	6 h	6 h	6 h
HKP-injected, untreated (n = 8)	3.5 ± 1.7	6.4 ± 1.1	14.7 ± 2.0	79.39 ± 0.30	8,783 ± 1,590
HKP-injected, pretreated with BQ788 (n = 5)	3.2 ± 1.1	4.5 ± 1.9	7.0 ± 3.4*	77.81 ± 0.63*	6,013 ± 1,410*
HKP-injected, treated with BQ788 at 4 h (n = 4)	4.1 ± 0.7	8.5 ± 1.0	15.5 ± 6.8	78.70 ± 1.01	8,569 ± 1,585
HKP-injected, pretreated with BQ123 (n = 7)	4.8 ± 1.4	8.2 ± 3.4	20.4 ± 7.9	79.90 ± 0.57	11,446 ± 1,921*
PBS-injected, pretreated with BQ788 (n = 3)	4.6 ± 0.2	4.4 ± 1.3	4.6 ± 1.3	77.53 ± 0.06	17 ± 12
PBS-injected, pretreated with BQ123 (n = 3)	3.7 ± 1.6	3.5 ± 1.4	3.0 ± 1.0	77.54 ± 0.52	15 ± 5
PBS-injected, untreated (n = 3)	5.5 ± 0.1	4.9 ± 0.9	5.5 ± 0.5	77.41 ± 0.16	14 ± 5

Challenge with HKP induced a significant increase in CBF_LDF, ICP, brain water content, and CSF WBC count (Fig. 1; Table 2). Pretreatment with BQ-788 significantly attenuated these pathophysiologic alterations (Fig. 1; Table 2). In contrast, pretreatment with BQ-123 failed to prevent the increase of ICP and brain water content seen after injection with HKP. Moreover, when injecting BQ-123, a significant increase in CBF_LDF and CSF pleocytosis was observed (Table 1).

FIG. 1.

Effect of pretreatment with either BQ-788 or BQ-123 on cerebral blood flow under both physiologic and pathophysiologic conditions. In untreated rats injected intracisternally with PBS (control rats; n = 3), there was no significant change in cerebral blood flow as measured by laser Doppler flowmetry (CBF_LDF) throughout the experiment. Intravenous administration of neither BQ-788 (n = 3) nor BQ-123 (n = 3) led to changes in CBF_LDF. Challenge with heat-killed pneumococci (n = 8) induced a significant increase in CBF_LDF. Pretreatment with BQ-788 (n = 5) significantly attenuated this pathophysiologic alteration (*P < 0.05; compared with both untreated rats injected intracisternally with heat-killed pneumococci and BQ-123–pretreated rats injected intracisternally with heat-killed pneumococci). When BQ-123 was injected (n = 7), a significant increase in CBF_LDF was even observed (#P < 0.05; compared with untreated rats injected intracisternally with heat-killed pneumococci).

Administration of BQ-788 4 hours after intracisternal challenge did not reverse the increase in CBF_LDF (6 hours after pneumococcal challenge: 196.1 ± 25.8%, compared with 225.3 ± 21.8% in untreated rats injected intracisternally with HKP; not significant) and ICP, and had no effect on brain edema formation and CSF pleocytosis (Table 2).

In vitro experiments

Nitrite concentrations in the cell culture supernatant of unstimulated endothelial cells (medium control) were below the detection limit. Stimulation with HKP induced a marked increase in nitrite levels (7.2 ± 1.8 μmol/L; P < 0.05 compared with medium control). Administration of l-NA prevented the increase in nitrite concentrations (0.9 ± 0.3 μmol/L; P < 0.05 compared with untreated endothelial cells stimulated with HKP). Treatment with phosphoramidon significantly reduced NO release by endothelial cells (2.7 ± 0.9 μmol/L; P < 0.05 compared with both medium control and untreated endothelial cells stimulated with HKP).

The ET concentration in cell culture supernatants of unstimulated endothelial cells (negative control) was 5.5 ± 2.4 pmol/L, suggesting a constitutive ET release. This result was supported by previous observations of immunoreactive ET-1 in the supernatants of bovine and rat micro vessel endothelial cells in short-term culture (Durieu-Trautmann et al., 1993; Yoshimoto et al., 1990). Stimulation with thrombin, a known inducer of ET secretion, caused a pronounced elevation of immunoreactive ET-1 in the cell culture medium (49.7 ± 23.6 pmol/L; P < 0.05 compared with negative control). Heat-killed pneumococci induced a significant increase in immunoreactive ET-1 (17.8 ± 2.7 pmol/L; P < 0.05 compared with negative control). No increase in immunoreactive ET-1 concentrations was detected when HKP were incubated in medium in the absence of endothelial cells. Treatment with phosphoramidon but not with l-NA significantly attenuated ET release on stimulation with HKP (7.9 ± 6.2 pmol/L and 13.3 ± 1.9 pmol/L, respectively).

DISCUSSION

The major finding of this study was that the ET_B receptor antagonist BQ-788 significantly attenuated the increase in CBF_LDF, ICP, brain water content, and CSF WBC count in early pneumococcal meningitis. There are three possible reasons for the failure of BQ-788 to completely inhibit pathophysiologic changes in our study: 1) involvement of other mediators than ET, 2) restricted access of peptidergic antagonists such as BQ-788 to the brain and, thus, to abluminal ET_B receptors, or 3) additional ET receptor subtypes, which cannot be blocked by BQ-788.

To date at least two distinct types of ET receptors have been described: ET_A and ET_B receptors. The ET_A receptor has a higher affinity for ET-1 and ET-2 than for ET-3, and the ET_B is nonselective for all three ET isopeptides (Sokolovsky, 1995). Pharmacologic data also support the existence of more than these two conventional receptor subtypes. For example, Wren and coworkers (1993) showed that whereas ET-3 can mediate cell proliferation in wounded human umbilical vein endothelial cells, neither ET-1 nor ET-2 can. This response cannot be mediated by the currently defined ET_A and ET_B receptors. In accordance with Wren and colleagues (1993), a third ET receptor subtype, which preferentially binds ET-3, was suggested to be expressed on bovine endothelial cells (Emori et al., 1990), rabbit vascular smooth muscle cells (Douglas et al., 1995), and in rat cerebellar homogenates (Widdowson and Kirk, 1996). This receptor subtype might be related to the ET_C receptor subtype, which was cloned from Xenopus laevis dermal melanophores (Karne et al., 1993). Since binding and functional data pointing to the existence of a third ET receptor subtype are scarce, and a mammalian homologue of this receptor has not yet been identified, it remains unclear whether the failure of BQ-788 to completely inhibit pathophysiologic changes in our study is related to the ET_C receptor.

The presence of receptors for ET in rat and human brain has been demonstrated in autoradiographic binding and in situ hybridization studies. Specific ET-binding sites were observed in neurons, astrocytes, microglial cells, vascular smooth muscle cells, and cerebromicrovascular endothelial cells (Rubanyi and Polokoff, 1994; Sokolovsky, 1995). The mammalian brain predominantly contains the ET_B receptor subtype (Fernandez-Durango et al., 1994). The ET_B receptor is believed to exist mainly on endothelial, neuronal, and glial cells (Harland et al., 1995; Lysko et al., 1995; Nilsson et al., 1997). The ET_A receptor is mainly expressed by vascular smooth muscle cells, but it is also abundant on endothelial, neuronal, and glial cells but to a far less degree (Vigne et al., 1990; Lysko et al., 1995; Nilsson et al., 1997). Studies report that ET-1 failed to cross the normal blood–brain barrier (Koseki et al., 1989). Similarly to ET, its peptidergic receptor antagonists, such as BQ-123 and BQ-788, presumably are unable to pass through the blood–brain barrier (Clozel and Watanabe, 1993). In our experiments, we found that BQ-788 had an effect when given by the intravenous route. The effect of BQ-788, as observed in our study, indicates that the agent is able to gain access to ET_B receptors mediating pathophysiologic alterations in pneumococcal meningitis. The most probable explanation is that ET_B receptors are located in the intravascular compartment, namely on cerebromicrovascular endothelial cells. Since the permeability of the blood–brain barrier is compromised during pneumococcal meningitis (Quagliarello et al., 1986), it is also conceivable that BQ-788 may gain direct access to abluminal ET_B receptors on glial and neuronal cells.

Another important finding of this study was that systemic administration of the ET_A receptor antagonist BQ-123 significantly augmented the increase in CBF_LDF and CSF WBC count. Our data on the efficacy of intravenous BQ-123 contradict most of the available information about the site of BQ-123 action in the brain. For example, Clozel and Watanabe (1993) demonstrated that BQ-123 prevented early cerebral vasospasm that follows subarachnoid hemorrhage after intracisternal but not intravenous injection. However, the observation of the effectiveness of intravenously administered BQ-123 in preventing cerebral postischemic hypoperfusion in gerbils agrees with our findings (Spatz et al., 1996). Moreover, Kobari et al. (1994a) describe a decline in cerebral blood volume after intracarotid administration of a low dose of ET-1; this was prevented with BQ-123 given by the same route. These authors suggest that BQ-123 may act on vasoconstrictive ET receptors located in the cerebrovascular endothelium.

Functional studies have pointed to a variety of biochemical effects elicited by activation of ET_A and ET_B receptors in the mammalian brain. Originally ET was described to be a highly potent vasoconstrictor (Yanagisawa et al., 1988). Although ET (i.e., ET-1) consistently has potent constrictive effects on isolated cerebral vessels in vitro (Salom et al., 1995), findings on the action of exogenous ET on the cerebral circulation in vivo vary. When applied from the abluminal side, ET-1 induced a pronounced constriction of cerebral arteries and a decrease in cerebral perfusion, which could be prevented by selective ET_A receptor antagonists (Rubanyi and Polokoff, 1994; Salom et al., 1995). Low doses of abluminal ET-1, however, occasionally may dilate pial arteries, probably through the induction of prostanoids and NO (Armstead et al., 1989). In addition, topical application of the ET_B receptor agonists IRL-1620 and BQ-3020 was shown to mediate dilation of rat basilar artery and feline cerebral resistance arterioles, which were dependent on NO production (Kitazono et al., 1995; Patel et al., 1996).

When ET was given intravascularly, ET was reported to have diverse effects on cerebral vessels: some observed a vasodilatory effect, whereas others reported either no or even a vasoconstrictive effect. Intraarterial infusion of ET-1 and BQ-3020 caused no change in diameters of canine major cerebral arteries or feline cerebral resistance arterioles, respectively (Shigeno et al., 1989; Patel et al., 1996). Even a decrease in cerebral perfusion was demonstrated after direct injection of ET-1 into the cerebral circulation of the goat (Salom et al., 1991). In contrast, an increase in cerebral perfusion was found after intracarotid infusion of high doses of either ET-1 or IRL-1620 in cats (Kobari et al., 1994a, 1994b). Similarly, Willette and others (1990) report increased cortical microvascular perfusion in rats either after intracarotid or intravenous administration of ET-1, and Weitzberg and associates (1993) describe cerebral vasodilation after intravenous infusion of ET-1 in humans. These discrepancies may depend on differences in vascular beds and species investigated in the aforementioned studies.

Since ET is constitutively produced by cerebrovascular endothelial cells, as observed in our and previous studies (Yoshimoto et al., 1990; Durieu-Trautmann et al., 1993), a basal ET-mediated cerebrovascular tone may be present. However, our observation that neither BQ-788 nor BQ-123 modulated CBF_LDF when administered in control rats contradicts this hypothesis, but agrees with a variety of recently published studies demonstrating that ET receptor antagonists have no effect on diameters of cerebral vessels or cerebral perfusion under physiologic conditions (Clozel and Watanabe, 1993; Kobari et al., 1994a).

The ET and ET receptor subtypes may play a major role in the pathophysiologic mechanisms of CNS diseases, namely, as a mediator of vasoconstriction and reduced cerebral perfusion. Three reasons support this suggestion: 1) far greater amounts of ET-1 have been detected in the CSF of patients with a variety of neurologic disorders such as cerebral ischemia and subarachnoid hemorrhage than in normal human CSF; 2) the expression of ET receptors was increased in the aforementioned diseases; and 3) inhibitors of ET production and selective ET receptor antagonists showed beneficial effects on the respective disease in animal models of the disease (Rubanyi and Polokoff, 1994; Salom et al., 1995).

In the current study, we report that BQ-788 attenuated the increase in CBF_LDF and CSF WBC count, whereas BQ-123 augmented these pathophysiologic alterations. There are several possible explanations for our observation. First, as mentioned earlier, the vasomotor effect of ET probably is composed of relaxant and contractile components that compete with each other. Blockade of ET_A receptors, which mainly mediate the vasoconstrictive effects of ET, may thus lead to some potentiation of ET-induced vasodilation and, therefore, to an enhanced increase in cerebral perfusion, as we observed. Second, ET_A blockade may be accompanied by a greater access of ET to ET_B receptors, thus amplifying ET_B receptor–mediated biochemical effects. Through ET_B receptor activation, ET was shown to stimulate its own production in rat aortic endothelial cells and in human umbilical endothelial cells (Fujitani et al., 1992; Saito et al., 1995), the synthesis of NO by bovine endothelial cells (Hirata et al., 1993), cytokine production by human umbilical endothelial cells (Stankova et al., 1996), prostacyclin release in guinea pig aortic rings (Matsuda et al., 1993), the expression of adhesion molecules on rat aortic endothelial cells (Hayasaki et al., 1996), and the enhancement of human neutrophil chemotaxis (Elferink and de Koster, 1996). In addition, ET-induced increases of either cerebral perfusion or diameters of cerebral vessels in cats and rats (Willette et al., 1990; Kobari et al., 1994a, 1994b), as well as an increase of the vascular permeability in the rat dura mater (Brändli et al., 1996), have been reported to be mediated by ET_B receptor activation. All of these biochemical and pathophysiologic mechanisms have been implicated in the pathophysiologic mechanism of pneumococcal meningitis. Thus, an amplification of these mechanisms may contribute to the observed augmentation of the increase in CBF_LDF and WBC counts after BQ-123 administration.

During the last several years, experimental studies have shown that the pathophysiologic mechanisms of pneumococcal meningitis are complex. Animal studies have provided evidence that cytokines (Saukkonen et al., 1990), arachidonic acid metabolites (Pfister et al., 1990), neuropeptides (Weber et al., 1996), reactive oxygen species (Pfister et al., 1990), NO (Koedel et al., 1995), and leukocyte–endothelial interaction (Tuomanen et al., 1989) are involved in the pathophysiologic mechanisms. Several reports indicate that ET may interact with these mediators: ET can stimulate the release of cytokines (Stankova et al., 1996), arachidonic acid metabolites (Matsuda et al., 1993), neuropeptides (Ritz et al., 1992), and NO (Hirata et al., 1993). Also, ET can up-regulate the expression of adhesion molecules including ICAM-1, VCAM-1, and E-selectin (McCarron et al., 1993; Hayasaki et al., 1996) and can induce neutrophil adhesion to endothelial cells (Hayasaki et al., 1996). Furthermore, ET can exert chemoattractant activity for neutrophils (Elferink and de Koster, 1996) and can modulate phagocyte function, such as potentiating fMet-Leu-Phe–activated superoxide production (Ishida et al., 1990).

In this study, cerebromicrovascular endothelial cells were induced to release both NO and ET on stimulation with pneumococci. Inhibition of the endothelin-converting enzyme with phosphoramidon prevented the increase in ET concentrations and markedly reduced NO release. These data help elucidate one possible mode of action of the ET_B receptor antagonist: BQ-788 inhibits ET-binding to ET_B receptors, thus reducing the generation of NO, which has been identified as a central mediator of pneumococcal meningitis (Koedel et al., 1995). The role of ET in the pathophysiologic mechanism of pneumococcal meningitis was supported by our previously published observation that elevated ET levels can be detected in CSF samples of patients with bacterial meningitis obtained on admission to the hospital (Koedel et al., 1997).

In conclusion, our data indicate that ET is a mediator in early pneumococcal meningitis in the rat and contributes to the increase in CBF_LDF, ICP, brain water content, and CSF pleocytosis, presumably by ET_B receptor–mediated NO production.

Acknowledgments: We thank Professor Dr. G. Ruckdeschel, Max-von-Pettenkofer-Institute of Hygiene and Microbiology, University of Munich, for preparation of pneumococci. We also thank Dr. A. Bernatowicz, Mrs. Heng, and Mrs. Bourquain for their excellent technical assistance; Mrs. J. Benson for copy editing; and Mrs. D. Förth for preparing the manuscript.

Footnotes

Abbreviations used

References

Arendt

Wilbert-Lampen

Heucke

Schmoeckel

Sühler

Richter

(1993) Increased endothelin plasma concentrations in patients with coronary artery disease or hyperlipoproteinemia without coronary events. Res Exp Med 193:225–230

Armstead

Mirro

Leffler

Busija

(1989) Influence of endothelin on piglet cerebral microcirculation. Am J Physiol 257:H707–H710

Brändli

Löffler

Breu

Osterwalder

Maire

Clozel

(1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64:315–322

Clozel

Watanabe

(1993) BQ-123, a peptidic endothelin ET_A receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 52:825–834

Corder

Carrier

Khan

Klemm

Vane

(1995) Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol 26 (suppl 3):S56–S58

Douglas

Beck

Elliott

Ohlstein

(1995) Pharmacological evidence for the presence of three functional endothelin receptor subtypes in the rabbit lateral saphenous vein. Br J Pharmacol 114:1529–1540

Durand

Calderwood

Weber

Miller

Southwick

Caviness

Swartz

(1993) Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 328:21–28

Durieu-Trautmann

Federici

Creminon

Foignant-Chaverot

Roux

Claire

Strosberg

Couraud

(1993) Nitric oxide and endothelin secretion by brain microvessel endothelial cells: regulation by cyclic nucleotides. J Cell Physiol 155:104–111

Ehrenreich

Anderson

Fox

Rieckmann

Hoffman

Travis

Coligan

Kehrl

Fauci

(1990) Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172:1741–1748

10.

Elferink

de Koster

(1996) Modulation of human neutrophil chemotaxis by the endothelin-B receptor agonist sarafotoxin S6c. Chem Biol Interact 101:165–174

11.

Emori

Hirata

Marumo

(1990) Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett 263:261–264

12.

Fernandez-Durango

de Juan

Zimman

Moya

Garcia de la Coba

Fernandez-Cruz

(1994) Identification of endothelin receptor subtype (ET_B) in human cerebral cortex using subtype-selective ligands. J Neurochem 62:1482–1488

13.

Fujitani

Oda

Takimoto

Inui

Okada

Urade

(1992) Autocrine receptors for endothelins in the primary culture of endothelial cells of human umbilical vein. FEBS Lett 298:79–83

14.

Harland

Kuc

Pickard

Davenport

(1995) Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Pharmacol 26 (Suppl 3):S408–S411

15.

Hayasaki

Nakajima

Kitano

Iwasaki

Shimamura

Iwaki

(1996) ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Biochem Biophys Res Commun 229:817–824

16.

Hirata

Emori

Eguchi

Kanno

Imai

Ohta

Marumo

(1993) Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91:1367–1373

17.

Ishida

Takeshige

Minakami

(1990) Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun 173:496–500

18.

Ishikawa

Ihara

Noguchi

(1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91:4892–4896

19.

Karne

Jayawickreme

Lerner

(1993) Cloning and characterization of an endothelin-3 specific receptor (ET_C receptor) from Xenopus laevis dermal melanophores. J Biol Chem 268:19126–19133

20.

Kitazono

Heistad

Faraci

(1995) Dilatation of the basilar artery in response to selective activation of endothelin B receptors in vivo. J Pharmacol Exp Ther 273:1–6

21.

Kobari

Fukuuchi

Tomita

Tanahashi

Konno

Takeda

(1994a) Constriction/dilatation of the cerebral microvessels by intravascular endothelin-1 in cats. J Cereb Blood Flow Metab 14:64–69

22.

Kobari

Fukuuchi

Tomita

Tanahashi

Konno

Takeda

(1994b) Dilatation of cerebral microvessels mediated by endothelin ET_B receptor and nitric oxide in cats. Neurosci Lett 176:157–160

23.

Koedel

Bernatowicz

Paul

Frei

Fontana

Pfister

H-W

(1995) Experimental pneumococcal meningitis: cerebrovascular alterations, brain edema, and meningeal inflammation are linked to the production of nitric oxide. Ann Neurol 37:313–323

24.

Koedel

Gorriz

Lorenzl

Pfister

H-W

(1997) Increased endothelin levels in the cerebrospinal fluid of adults with bacterial meningitis. Clin Infect Dis 25:329–330

25.

Koseki

Imai

Hirata

Yanagisawa

Masaki

(1989) Autoradiographic distribution in rat tissue of binding sites for endothelin: a neuropeptide? Am J Physiol 256:R858–R866

26.

Lysko

Elshourbagy

Pullen

Nambi

(1995) Developmental expression of endothelin receptors in cerebellar neurons differentiating in culture. Brain Res Dev Brain Res 88:96–101

27.

Matsuda

Beppu

Ohmori

Yamada

Miyatake

(1993) Involvement of cyclooxygenase-generated vasodilating eicosanoid(s) in addition to nitric oxide in endothelin-1–induced endothelium-dependent vasorelaxation in guinea pig aorta. Heart Vessels 8:121–127

28.

McCarron

Wang

Stanimirovic

Spatz

(1993) Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci Lett 156:31–34

29.

Nilsson

Cantera

Adner

Edvinsson

(1997) Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries. Neurosurgery 40:346–351

30.

Patel

McAuley

McCulloch

(1996) Endothelin receptor mediated constriction and dilatation in feline cerebral resistance arterioles in vivo. Eur J Pharmacol 307:41–48

31.

Pfister

Koedel

Haberl

Dirnagl

Feiden

Ruckdeschel

Einhaupl

(1990) Microvascular changes during the early phase of experimental bacterial meningitis. J Cereb Blood Flow Metab 10:914–922

32.

Quagliarello

Long

Scheld

(1986) Morphologic alterations of the blood–brain barrier with experimental meningitis in the rat. Temporal sequence and role of encapsulation. J Clin Invest 77:1084–1095

33.

Quagliarello

Scheld

(1992) Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 327:864–872

34.

Ritz

M-F

Stuenkel

Dayanithi

Jones

Nordmann

(1992) Endothelin regulation of neuropeptide release from nerve endings of the posterior pituitary. Proc Natl Acad Sci USA 89:8371–8375

35.

Rubanyi

Polokoff

(1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46:325–415

36.

Saito

Hirata

Imai

Marumo

(1995) Autocrine regulation of the endothelin-1 gene in rat endothelial cells. J Cardiovasc Pharmacol 26 (suppl 3):S84–S87

37.

Salom

Torregrosa

Alborch

(1995) Endothelins and the cerebral circulation. Cerebrovasc Brain Metab Rev 7:131–152

38.

Salom

Torregrosa

Miranda

Alabadi

Alvarez

Alborch

(1991) Effects of endothelin-1 on the cerebrovascular bed of the goat. Eur J Pharmacol 192:39–45

39.

Saukkonen

Sande

Cioffe

Wolpe

Sherrry

Cerami

Tuomanen

(1990) The role of cytokines in the generation of inflammation and tissue damage in experimental pmeumococcal meningitis. J Exp Med 171:439–448

40.

Shigeno

Mima

Takakura

Yanagisawa

Saito

Goto

Masaki

(1989) Endothelin-1 acts in cerebral arteries from the adventitial but not from the luminal side. J Cardiovasc Pharmacol 13 Suppl 5:S174–S176

41.

Sokolovsky

(1995) Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Pharmacol Ther 68:435–471

42.

Spatz

Yasuma

Strasser

McCarron

(1996) Cerebral postischemic hypoperfusion is mediated by ET_A receptors. Brain Res 726:242–246

43.

Stanimirovic

McCarron

Bertrand

Spatz

(1993) Endothelins release ⁵¹Cr from cultured human cerebromicrovascular endothelium. Biochem Biophys Res Commun 191:1–8

44.

Stankova

D'Orleans-Juste

Rola-Pleszczynski

(1996) ET-1 induces IL-6 gene expression in human umbilical vein endothelial cells: synergistic effect of IL-1. Am J Physiol 271:C1073–C1078

45.

Tuomanen

(1996) Entry of pathogens into the central nervous system. FEMS Microbiol Rev 18:289–299

46.

Tuomanen

Saukkonen

Sande

Cioffe

Wright

(1989) Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med 170:959–969

47.

Vigne

Marsault

Breittmayer

Frelin

(1990) Endothelin stimulates phosphatidylinositol hydrolysis and DNA synthesis in brain capillary endothelial cells. Biochem J 266:415–420

48.

Weber

Angstwurm

Bove

Bürger

Einhäupl

Dirnagl

Moskowitz

(1996) The trigeminal nerve and augmentation of regional cerebral blood flow during experimental bacterial meningitis. J Cereb Blood Flow Metab 16:1319–1324

49.

Weitzberg

Ahlborg

Lundberg

(1993) Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol 13:653–662

50.

Widdowson

Kirk

(1996) Characterization of [¹²⁵I]-endothelin-1 and [¹²⁵I]-BQ3020 binding to rat cerebellar endothelin receptors. Br J Pharmacol 118:2126–2130

51.

Willette

Sauermelch

Ezekiel

Feuerstein

Ohlstein

(1990) Effect of endothelin on cortical microvascular perfusion in rats. Stroke 21:451–458

52.

Wren

Hiley

Fan

T-PD

(1993) Endothelin-3 mediated proliferation in wounded human umbilical vein endothelial cells. Biochem Biophys Res Commun 196:369–375

53.

Yanagisawa

Kurihara

Kimura

Tomobe

Kobayashi

Mitsui

Yazaki

Goto

Masaki

(1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 31:411–415

54.

Yoshimoto

Ishizaki

Kurihara

Sasaki

Yoshizumi

Yanagisawa

Yazaki

Masaki

Takakura

Murota

S-I

(1990) Cerebral microvessel endothelium is producing endothelin. Brain Res 508:283–285

Endothelin B Receptor–Mediated Increase of Cerebral Blood Flow in Experimental Pneumococcal Meningitis

Abstract

Keywords

METHODS

Rat model of pneumococcal meningitis

Induction of meningitis

Experimental protocol of in vivo investigations

In vitro experiments

Preparation of cerebromicrovascular endothelial cells

Experimental groups of in vitro experiments

Determination of nitrite and endothelin concentrations in the cell culture medium

Reagents

Statistical analysis

RESULTS

In vivo experiments

In vitro experiments

DISCUSSION

Footnotes

Abbreviations used

References